AGF Investments America Inc. lowered its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 21.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,911 shares of the medical research company’s stock after selling 13,428 shares during the period. Thermo Fisher Scientific accounts for 3.3% of AGF Investments America Inc.’s holdings, making the stock its 5th biggest position. AGF Investments America Inc.’s holdings in Thermo Fisher Scientific were worth $8,534,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Sharkey Howes & Javer raised its holdings in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the last quarter. Beacon Trust Co. raised its holdings in shares of Thermo Fisher Scientific by 0.6% in the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock worth $341,000 after buying an additional 12 shares during the last quarter. Reinhart Partners Inc. raised its holdings in shares of Thermo Fisher Scientific by 0.6% in the second quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock worth $598,000 after buying an additional 20 shares during the last quarter. Azimuth Capital Management LLC raised its holdings in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock worth $493,000 after buying an additional 25 shares during the last quarter. Finally, Savant Capital LLC raised its holdings in shares of Thermo Fisher Scientific by 1.0% in the second quarter. Savant Capital LLC now owns 2,793 shares of the medical research company’s stock worth $487,000 after buying an additional 29 shares during the last quarter. 83.36% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/10/13/thermo-fisher-scientific-inc-tmo-shares-sold-by-agf-investments-america-inc.html.

In related news, Director C Martin Harris sold 360 shares of the stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares in the company, valued at approximately $961,312.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Seth H. Hoogasian sold 4,140 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the sale, the vice president now owns 25,518 shares of the company’s stock, valued at approximately $4,537,100.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,738 shares of company stock valued at $9,302,112. 0.49% of the stock is owned by company insiders.

TMO has been the subject of a number of research analyst reports. BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 27th. Citigroup Inc. reaffirmed a “buy” rating and issued a $201.00 price target (up previously from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 price target for the company in a report on Tuesday, July 11th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $200.00 price target (up previously from $195.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 13th. Finally, Barclays PLC reaffirmed an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average price target of $203.64.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. Thermo Fisher Scientific’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.03 EPS.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.